FGFR3 encodes fibroblast growth factor receptor 3, a protein that carries signals across the cell membrane. Different alterations can be associated with different clinical conditions. A result must therefore specify the variant, its mechanism and the context in which it was found; the gene name alone is not an adequate diagnosis. [1]

In this guide: What is a growth-factor receptor? · What are the common achondroplasia findings? · Does every FGFR3 variant mean achondroplasia? · A step-by-step FGFR3 report review · How should inheritance be discussed? · How do mechanism and clinical benefit differ? · Move from a gene name to a clear question

What is a growth-factor receptor?

The receptor receives signals outside a cell and activates pathways inside it. FGFR3 participates in regulation of skeletal growth, including the process in which cartilage is replaced by bone. The common achondroplasia variants make the receptor overly active. More signaling does not necessarily mean more growth: the effect depends on the biological pathway. [1]

In a research notebook, label the receptor, the signal measured and the biological outcome separately. If an experiment reports pathway activation, do not rewrite that observation as an established change in a person’s height or function. Those outcomes require their own clinical evidence.

FGFR3 evidence map separates the exact alteration, biological effect, clinical explanation and intervention outcomes.
FGFR3 evidence map separates the exact alteration, biological effect, clinical explanation and intervention outcomes. Original educational schematic; see article for sources and limits.

Open full-size illustration (new tab)

What are the common achondroplasia findings?

Two recurrent DNA changes, commonly described as c.1138G>A and c.1138G>C, both produce p.Gly380Arg in the relevant FGFR3 transcript. They account for almost all achondroplasia cases. Exact transcript and version should always be retained when comparing a clinical report with a publication. [2]

The molecular result belongs alongside the clinical and radiographic assessment. A variant of uncertain significance does not establish or exclude achondroplasia by itself. If the presentation is not explained, the team may consider other skeletal conditions and a different testing strategy. [2]

Does every FGFR3 variant mean achondroplasia?

No. FGFR3 variants are associated with other skeletal diagnoses, including hypochondroplasia and thanatophoric dysplasia, as well as other tissue-specific conditions. Somatic changes can also occur in localized tissues or cancers. The exact alteration and where it is present are central to interpretation. [1]

A useful comparison table has one row for each report, with columns for variant, specimen, classification, associated condition and supporting clinical findings. Do not combine rows because the gene symbol matches. Our tumor versus germline testing guide explains why a tumor result and a constitutional result answer different questions.

A step-by-step FGFR3 report review

  1. Identify the question: skeletal diagnosis, family testing, tumor testing or another indication?
  2. Preserve the notation: retain the transcript/version, DNA and protein change.
  3. Check the conclusion: copy the laboratory’s classification and condition without strengthening its wording.
  4. Read the method: was testing targeted to common changes or designed to assess a broader range?
  5. Connect the phenotype: list the findings explained and those still unresolved.
  6. Clarify follow-up: ask who will discuss clinical implications and family questions.

Consider a teaching example in which a test examined only the recurrent achondroplasia variants and found neither. That statement does not mean that every FGFR3 alteration or every skeletal condition was excluded. The report’s scope must remain visible in any summary. Our analytical sensitivity guide develops this distinction.

How should inheritance be discussed?

Achondroplasia is autosomal dominant and often arises through a de novo change. Family counseling must consider both parents’ circumstances, especially when both have a skeletal condition. A result is not evidence that a parent’s behavior caused the condition. [3]

For a family appointment, write the confirmed diagnoses and actual test results in separate entries. Include the relationship between people without assigning results to anyone who has not been tested. Ask which question parental testing would answer and which uncertainties it cannot resolve.

How do mechanism and clinical benefit differ?

A gain-of-function mechanism can provide a rationale for studying an intervention, but it does not by itself demonstrate clinical benefit. Ask whether a study measures signaling, growth, function, complications or patient experience. Record how the model or trial population relates to the people for whom a benefit is claimed.

The international achondroplasia consensus frames care as lifelong and multidisciplinary, addressing medical, functional and psychosocial needs. That broader framework is useful when judging whether a research endpoint captures only one part of the condition. [4]

For journal club, make a five-column worksheet: proposed mechanism, experiment, observed result, clinical claim and remaining uncertainty. This helps avoid the leap from a successful laboratory manipulation to an unsupported promise about daily life. Use the functional evidence guide to evaluate controls and relevance.

Move from a gene name to a clear question

The achondroplasia care guide covers appointments and support. Use the variant research assistant, literature tools and care finder for non-identifying research and specialist services. An online search cannot classify a personal variant or select a treatment.

Educational information, not an individual diagnosis or treatment plan. The current specialist-review status appears above. Illustrations are original educational examples, not patient records.